← Back to screener

Prelude Therapeutics Inc PRLD

Rank #2140 · Nasdaq · $0.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
32.4
P/E
-2.4
P/B
1.30
ROE
-53.6%
Op. Margin
-1995.9%
Debt Ratio
19%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -2.4x, P/B 1.30x. Ranks in the top 57% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -53.6%. Ranks in the top 93% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 19%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★★☆☆☆
Weak

Revenue growth of 0.0% year over year. Ranks in the top 64% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-21
2021–$-0.1B$-0.1B$-0.0B–-23
2022–$-0.1B$-0.1B$0.2B–9
2023–$-0.1B$-0.1B$0.3B–9
2024$0.0B$-0.1B$-0.1B$0.2B-1889.721
2025$0.0B$-0.1B$-0.1B$0.2B-1995.919

← See the full screener